Navigation Links
Grifols Breaks Ground on New IVIG Facility

The new facility, based in Los Angeles, California is anticipated to be operational in 2013 and will expand the Company's ability to supply its new generation of intravenous immune globulin into the foreseeable future.

LOS ANGELES, Oct. 6 /PRNewswire/ -- Today, Grifols SA (Grifols), a global healthcare company based in Barcelona, Spain, broke ground on a new 92,000 square foot, intravenous immune globulin (IVIG) production facility at its manufacturing complex in Los Angeles, California. This new facility is the initial realization of the $600 million long-range investment plan announced in October 2007 to increase production for Grifols lifesaving coagulation therapies, immune globulins and albumin. Based on construction schedules and rigorous regulatory licensing requirements, it is expected that the facility will become operational for production of the Company's new generation IVIG product in early 2013.

The new facility represents an expansion of Grifols' existing manufacturing capabilities in Los Angeles. "We are committed to continuing to grow our state of the art facilities in Los Angeles and giving back to the community through the creation of new employment opportunities and economic growth," said Gregory Rich, President of Grifols, Inc. the US subsidiary of Grifols, SA. The new facility will provide approximately 300 new jobs to the Los Angeles community and represents an investment of greater than $50 million.

"We commend Grifols' increased commitment to the production of immune globulin therapy. Assuring continued access to this lifesaving medicine means countless people who live with primary immunodeficienies, such as my son, can lead healthy and productive lives," said Marcia Boyle, President and Founder of the Immune Deficiency Foundation, the national patient organization for persons with primary immune diseases. Demand for IVIG has seen steady growth over the past ten years in the US, Europe and other international markets.

Grifols' new production facility will almost double the company's IVIG production capacity and will utilize the same proprietary technologies and process flow designs employed at the company's existing IVIG production facility in Barcelona, Spain that have been pioneered by Grifols Engineering S.A., a wholly owned subsidiary of Grifols S.A. In effect, the new facility will be a twin of the Company's IVIG facility in Barcelona, Spain that was licensed by the US Food and Drug Administration (FDA) last year.

Building this additional production capacity represents one more step in Grifols' multi-year global growth plan to meet increasing patient need for lifesaving plasma therapies. Other elements of the long-range investment plan include expanding plasma collection capacity and additional production and testing facilities. Earlier this year the Company obtained FDA approval of its state of the art bulk processing and aseptic filling facility at its Los Angeles manufacturing complex.

About Grifols

Grifols SA (Grifols) is a global healthcare company founded in 1940 in Barcelona, Spain. Today Grifols products and services are provided in more than 90 countries around the world. Grifols specializes in the production of plasma therapies to treat a variety of life-threatening diseases and conditions. Grifols operates 80 plasma donor centers throughout the US and has manufacturing facilities located in Barcelona, Spain and Los Angeles, California. For more information about Grifols please visit

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Companys North American Headquarters
2. Kansas Breaks Into Top 10 in the Nation in Biotech Strength
3. NASA technology helps predict and prevent future pandemic outbreaks
4. Novel Technology Breaks Through Cancer Pain
5. In novel playground, metals are formed into porous nanostructures
6. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
7. Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates
8. Liberty Screening Services Hires Top Executive to Meet Explosive Demand for its Background-Screening Services
9. A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy
10. Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer
11. Easily Lift, Transfer and Reposition Patients with Ground-Breaking Liftaem(TM) System from Smart Medical Technology, Inc.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
Breaking Biology News(10 mins):